

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ERICH WANKER, et al.

Application No.: 10/589,276

Group Art Unit: To be assigned

Filed: August 10, 2006

Examiner: To be assigned

Confirmation No.: 5727

For: NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE
TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR
AMYLOID DISEASES

PETITION UNDER 37 C.F.R. §1.182

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicant's hereby petition under 37 C.F.R. §1.182 that the Response to Notification of Missing Requirements and Decision filed on March 10, 2008 be accepted and entered. Applicant's submit herewith executed Statements of Phoebe Markovic and Dagmar Ehrnhöfer to accompany this Petition Under 37 C.F.R. §1.182.

The petition fees of \$190.00 are submitted, as required by 37 C.F.R. §§ 1.17(h) and 1.136(a).

Petition for Extension of Time:

Applicant hereby petitions for an extension of time to extend the time period for reply from July 12, 2008 to August 12, 2008. The Commissioner is authorized to charge Deposit Account 033975, Order No. 009848-0356193, for the requisite extension fee and any other fees due in connection with this submission.

Date: August 12, 2008


Robert M. Bedgood
Reg. No. 43,488
PILLSBURY WINTHROP SHAW PITTMAN LLP
12255 El Camino Real, Suite 300
San Diego, CA 92130-4088
Tel: (619) 234-5000
Fax: (858) 509-4010
Customer No. 27500

CERTIFICATION UNDER 37 C.F.R. §§ 1.8 and/or 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*; Express Mail certification is *optional*.)


I hereby certify that, on the date shown below, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: _____

Signature

(type or print name of person certifying)

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.



Attorney Docket No. 009848-0356193
Client Reference: K1577 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ERICH WANKER, et al.

Application No.: 10/589,276

Group Art Unit: To be assigned

Filed: August 10, 2006

Examiner: To be assigned

Confirmation No.: 5727

For: NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE
TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR
AMYLOID DISEASES

**STATEMENTS OF PHOEBE MARKOVIC AND DAGMAR EHRNHÖFER TO
ACCOMPANY PETITION UNDER 37 C.F.R. §1.182**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

We, Phoebe Markovic and Dagmar Ehrnhöfer, do hereby declare and state that:

1. I, Phoebe Markovic, attest that I am the same inventor as named in published International Application No. PCT/EP05/01389, filed February 11, 2005, entitled "NOVEL PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIOSN FOR USE IN THE TREATMENT AND ADIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES" and that I am the same inventor of U.S. Application No. 10/589,276, filed August 10, 2006. I also attest that after the filing of the International Application my name changed from Phoebe Harjes to Phoebe Markovic.

2. I, Dagmar Ehrnhöfer, attest that I am the same inventor as named in published International Application No. PCT/EP05/01389, filed February 11, 2005, entitled "NOVEL PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIOSN FOR USE IN THE TREATMENT AND ADIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES" and that I am the same inventor of U.S. Application No.

10/589,276, filed August 10, 2006. I also attest that after the filing of the International Application my name changed from Dagmar Litscher to Dagmar Ehrnhöfer.

3. We declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Phoebe Markovic

Date: _____



Dagmar Ehrnhöfer

Date: June 15th, 2008

Attorney Docket No. 009848-0356193
Client Reference: K1577 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ERICH WANKER, et al.

Application No.: 10/589,276

Group Art Unit: To be assigned

Filed: August 10, 2006

Examiner: To be assigned

Confirmation No.: 5727

For: NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE
TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR
AMYLOID DISEASES

**STATEMENTS OF PHOEBE MARKOVIC AND DAGMAR EHRNHÖFER TO
ACCOMPANY PETITION UNDER 37 C.F.R. §1.182**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

We, Phoebe Markovic and Dagmar Ehmhöfer, do hereby declare and state that:

1. I, Phoebe Markovic, attest that I am the same inventor as named in published International Application No. PCT/EP05/01389, filed February 11, 2005, entitled "NOVEL PHARMACEUTICAL AND DIAGNOSTIC COMPOSITOSN FOR USE IN THE TREATMENT AND ADIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES" and that I am the same inventor of U.S. Application No. 10/589,276, filed August 10, 2006. I also attest that after the filing of the International Application my name changed from Phoebe Harjes to Phoebe Markovic.

2. I, Dagmar Ehmhöfer, attest that I am the same inventor as named in published International Application No. PCT/EP05/01389, filed February 11, 2005, entitled "NOVEL PHARMACEUTICAL AND DIAGNOSTIC COMPOSITOSN FOR USE IN THE TREATMENT AND ADIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES" and that I am the same inventor of U.S. Application No.

10/589,276, filed August 10, 2006. I also attest that after the filing of the International Application my name changed from Dagmar Litscher to Dagmar Ehmhöfer.

3. We declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Phoebe Markovic
Phoebe Markovic

Date: 17 July 2008

Dagmar Ehmhöfer

Date: _____